Shield Therapeutics PLC is a specialty pharmaceutical company focused on addressing iron deficiency. It develops and commercializes ACCRUFeR®, a non-salt based oral treatment for adults with iron deficiency, regardless of anaemia status. The company operates through partnerships, primarily with Viatris, to drive prescription demand and optimize distribution channels in the U.S. Shield is also expanding its product indications to include children and supports global licensing partners in various markets, including Japan, South Korea, China, Canada, and Europe.